Plasma enhance drug sensitivity to bortezomib by inhibition of cyp1a1 in myeloma cells.

Authors:
Xu D; Cui Q; Xu Y; Chen Z; Xia W and 2 more

Journal:
Transl Cancer Res

Publication Year: 2019

DOI:
10.21037/tcr.2019.10.43

PMCID:
PMC8798238

PMID:
35117041

Journal Information

Full Title: Transl Cancer Res

Abbreviation: Transl Cancer Res

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Oncology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
2/6
0.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/tcr.2019.10.43). The authors have no conflicts of interest to declare."

Evidence found in paper:

"Funding: This work is supported by the National Natural Science Foundation of China ( Grant No. 51521065 ), First Class of China Postdoctoral Science Foundation ( 2017M610639 ) and Special Fund of China Postdoctoral Science Foundation, the Fundamental Research Funds for Central Universities, State Key Laboratory of Electrical Insulation and Power Equipment ( EIPE18312 ) and Special Fund of Shaanxi Postdoctoral Science Foundation ( 2017BSHTDZZ04 )."

Protocol Registration
Open Access
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025